Nanomedicine Combats Drug Resistance in Lung Cancer
Source abstract
Abstract
Abstract Lung cancer is the second most prevalent cancer and the leading cause of cancer‐related death worldwide. Surgery, chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy are currently available as treatment methods. However, drug resistance is a significant factor in the failure of lung cancer treatments. Novel therapeutics have been exploited to address complicated resistance mechanisms of lung cancer and the advancement of nanomedicine is extremely promising in terms of overcoming drug resistance. Nanomedicine equipped with multifunctional and tunable physiochemical properties in alignment with tumor genetic profiles can achieve precise, safe, and effective treatment while minimizing or eradicating drug resistance in cancer. Here, this work reviews the discovered resistance mechanisms for lung cancer chemotherapy, molecular targeted therapy, immunotherapy, and radiotherapy, and outlines novel strategies for the development of nanomedicine against drug resistance. This work focuses on engineering design, customized delivery, current challenges, and clinical translation of nanomedicine in the application of resistant lung cancer.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Peptidase Inhibition and Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Radiology Department of Respiratory Huaxi MR Research Center (HMRRC) and Critical Care Medicine Institute of Respiratory Health Precision Medicine Center Frontiers Science Center for Disease‐Related Molecular Network State Key Laboratory of Biotherapy West China Hospital Sichuan University No. 37 Guoxue Alley Chengdu 610041 China
Department of General Surgery Gastric Cancer Center and Laboratory of Gastric Cancer West China Hospital Sichuan University No. 37 Guoxue Alley Chengdu 610041 China
Precision Medicine Key Laboratory of Sichuan Province Functional and Molecular Imaging Key Laboratory of Sichuan Province and Research Unit of Psychoradiology Chinese Academy of Medical Sciences Chengdu 610041 China
Department of Radiology West China Xiamen Hospital of Sichuan University Xiamen Fujian 361000 China
Funding
National Natural Science Foundation of China · National Postdoctoral Program for Innovative Talents
References (100+)
Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.1158/1055-9965.EPI-19-022110.1158/1055-9965.EPI-19-0221 ↗
3. 10.1056/NEJMoa191662310.1056/NEJMoa1916623 ↗
4. 10.1016/S0140-6736(21)00312-310.1016/S0140-6736(21)00312-3 ↗
5. 10.1038/s43018-021-00195-810.1038/s43018-021-00195-8 ↗
6. 10.1158/1078-0432.CCR-18-153810.1158/1078-0432.CCR-18-1538 ↗
7. 10.1038/nrclinonc.2014.10410.1038/nrclinonc.2014.104 ↗
8. 10.1038/s41591-021-01450-210.1038/s41591-021-01450-2 ↗
9. 10.1021/acs.chemrev.5b0011610.1021/acs.chemrev.5b00116 ↗
10. 10.1016/j.jconrel.2020.07.00710.1016/j.jconrel.2020.07.007 ↗
11. 10.1038/s41568-022-00496-910.1038/s41568-022-00496-9 ↗
12. 10.1038/s41565-019-0567-y10.1038/s41565-019-0567-y ↗
13. 10.1039/D1CS00468A10.1039/D1CS00468A ↗
14. 10.1039/D2CS00437B10.1039/D2CS00437B ↗
15. 10.1016/j.jconrel.2021.05.01210.1016/j.jconrel.2021.05.012 ↗
16. 10.1016/j.drup.2020.10070410.1016/j.drup.2020.100704 ↗
17. 10.1038/s41572-020-00235-010.1038/s41572-020-00235-0 ↗
18. 10.1016/S1470-2045(20)30539-810.1016/S1470-2045(20)30539-8 ↗
19. 10.1016/j.jtho.2019.10.00410.1016/j.jtho.2019.10.004 ↗
20. 10.1016/j.jtho.2019.12.10910.1016/j.jtho.2019.12.109 ↗
21. 10.1093/annonc/mdz264.00210.1093/annonc/mdz264.002 ↗
22. 10.1016/j.jtho.2018.08.30810.1016/j.jtho.2018.08.308 ↗
23. 10.1038/s41416-019-0583-610.1038/s41416-019-0583-6 ↗
24. 10.1126/sciadv.abn122910.1126/sciadv.abn1229 ↗
25. 10.1038/s41571-021-00501-410.1038/s41571-021-00501-4 ↗
26. 10.1001/jama.2019.1105810.1001/jama.2019.11058 ↗
27. 10.1038/nature2518310.1038/nature25183 ↗
28. 10.1038/s41392-019-0099-910.1038/s41392-019-0099-9 ↗
29. 10.1038/nrc.2017.8410.1038/nrc.2017.84 ↗
30. 10.1016/j.ctrv.2019.03.00410.1016/j.ctrv.2019.03.004 ↗
31. 10.1056/NEJMoa180100510.1056/NEJMoa1801005 ↗
32. 10.1200/JCO.21.0149710.1200/JCO.21.01497 ↗
33. 10.1038/s41586-019-1730-110.1038/s41586-019-1730-1 ↗
34. 10.1016/j.ccell.2020.03.00710.1016/j.ccell.2020.03.007 ↗
35. 10.3390/ijms2313724110.3390/ijms23137241 ↗
36. 10.1016/j.ejmech.2020.11257010.1016/j.ejmech.2020.112570 ↗
37. 10.1016/j.cllc.2020.01.00610.1016/j.cllc.2020.01.006 ↗
38. 10.1093/annonc/mdz27810.1093/annonc/mdz278 ↗
39. 10.1007/s00432-020-03129-610.1007/s00432-020-03129-6 ↗
40. 10.1111/1759-7714.1332810.1111/1759-7714.13328 ↗
41. 10.1158/1078-0432.CCR-18-414010.1158/1078-0432.CCR-18-4140 ↗
42. 10.1016/j.semcancer.2022.11.00610.1016/j.semcancer.2022.11.006 ↗
43. 10.1158/1078-0432.CCR-07-223810.1158/1078-0432.CCR-07-2238 ↗
44. 10.1038/nrc216710.1038/nrc2167 ↗
45. 10.1158/0008-5472.CAN-05-109510.1158/0008-5472.CAN-05-1095 ↗
46. 10.1016/j.critrevonc.2007.02.00110.1016/j.critrevonc.2007.02.001 ↗
47. 10.3389/fphar.2020.0034310.3389/fphar.2020.00343 ↗
48. 10.3892/ol_0000004910.3892/ol_00000049 ↗
49. 10.1186/1479-5876-10-2110.1186/1479-5876-10-21 ↗
50. Young L. C. · Clin. Cancer Res. · 2001 · 7 · 1798
51. 10.1016/j.drup.2020.10069110.1016/j.drup.2020.100691 ↗
52. 10.1038/s41598-019-54065-610.1038/s41598-019-54065-6 ↗
53. 10.1038/s41389-017-0025-310.1038/s41389-017-0025-3 ↗
54. 10.1371/journal.pone.018108110.1371/journal.pone.0181081 ↗
55. 10.1038/cddis.2012.21110.1038/cddis.2012.211 ↗
56. 10.1080/15384047.2017.134539110.1080/15384047.2017.1345391 ↗
57. 10.1038/srep1229110.1038/srep12291 ↗
58. 10.1186/s12943-018-0793-110.1186/s12943-018-0793-1 ↗
59. 10.1158/1078-0432.CCR-10-002010.1158/1078-0432.CCR-10-0020 ↗
60. 10.1158/1535-7163.MCT-15-006210.1158/1535-7163.MCT-15-0062 ↗
61. 10.1038/s41419-019-1591-410.1038/s41419-019-1591-4 ↗
62. 10.1016/j.biopha.2019.10913510.1016/j.biopha.2019.109135 ↗
63. 10.1016/j.ccell.2018.06.01210.1016/j.ccell.2018.06.012 ↗
64. 10.1038/onc.2009.45410.1038/onc.2009.454 ↗
65. Zhao J. · Int. J. Oncol. · 2020 · 56 · 1083
66. 10.3390/cancers301142610.3390/cancers3011426 ↗
67. 10.1038/nrclinonc.2017.4410.1038/nrclinonc.2017.44 ↗
68. 10.3892/mmr.2016.488210.3892/mmr.2016.4882 ↗
69. 10.1158/0008-5472.CAN-16-163310.1158/0008-5472.CAN-16-1633 ↗
70. 10.1038/s41419-021-03435-y10.1038/s41419-021-03435-y ↗
71. 10.1016/j.freeradbiomed.2019.03.00910.1016/j.freeradbiomed.2019.03.009 ↗
72. 10.3389/fonc.2021.83514110.3389/fonc.2021.835141 ↗
73. 10.1016/j.canlet.2017.07.02710.1016/j.canlet.2017.07.027 ↗
74. 10.1111/cas.1399810.1111/cas.13998 ↗
75. 10.1186/s13046-019-1166-310.1186/s13046-019-1166-3 ↗
76. 10.1038/s41419-021-04033-810.1038/s41419-021-04033-8 ↗
77. Wangpaichitr M. · Cell Dev. Biol. · 2017 · 6 · 183
78. 10.1016/j.cellsig.2020.10987110.1016/j.cellsig.2020.109871 ↗
79. 10.1038/nrc280310.1038/nrc2803 ↗
80. 10.3390/ijms1807143410.3390/ijms18071434 ↗
81. 10.1038/s41420-021-00453-910.1038/s41420-021-00453-9 ↗
82. 10.1158/0008-5472.991.65.310.1158/0008-5472.991.65.3 ↗
83. 10.1016/j.biopha.2017.10.04110.1016/j.biopha.2017.10.041 ↗
84. 10.1038/srep0312010.1038/srep03120 ↗
85. 10.18632/oncotarget.694510.18632/oncotarget.6945 ↗
86. 10.7150/ijbs.2883410.7150/ijbs.28834 ↗
87. 10.1007/s13277-015-3361-y10.1007/s13277-015-3361-y ↗
88. 10.1038/nrc.2017.9610.1038/nrc.2017.96 ↗
89. 10.1016/j.ctrv.2011.07.00810.1016/j.ctrv.2011.07.008 ↗
90. 10.1016/j.prp.2022.15405310.1016/j.prp.2022.154053 ↗
91. 10.1016/j.biopha.2021.11182410.1016/j.biopha.2021.111824 ↗
92. 10.1016/j.intimp.2022.10855510.1016/j.intimp.2022.108555 ↗
93. 10.1186/s12931-019-1071-510.1186/s12931-019-1071-5 ↗
94. 10.1002/tox.2289110.1002/tox.22891 ↗
95. 10.1158/0008-5472.CAN-17-060410.1158/0008-5472.CAN-17-0604 ↗
96. 10.2119/molmed.2011.0023010.2119/molmed.2011.00230 ↗
97. 10.1038/s41419-020-2600-310.1038/s41419-020-2600-3 ↗
98. 10.1016/j.drup.2019.10067310.1016/j.drup.2019.100673 ↗
99. 10.1038/s41419-022-04727-710.1038/s41419-022-04727-7 ↗
100. 10.1038/nature2232310.1038/nature22323 ↗